Results 181 to 190 of about 15,200 (191)

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Lancet, The, 2016
Sagar Lonial, Saad Z Usmani, Ajai Chari
exaly  

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

Leukemia, 2020
Nizar J Bahlis, , Merav Leiba
exaly  

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine, 2016
Antonio Palumbo, Katja C Weisel, Ajay K Nooka   +2 more
exaly  

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine, 2016
Albert Oriol, Hareth Nahi, Jesus San Miguel   +2 more
exaly  

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

Leukemia, 2020
Niels W C J Van De Donk, Yann Abraham, Hugo Ceulemans   +2 more
exaly  

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

New England Journal of Medicine, 2018
María-Victoria Mateos, Michele Cavo, 鈴木 憲史   +2 more
exaly  

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

New England Journal of Medicine, 2019
Thierry Facon, Shaji K Kumar, Torben Plesner   +2 more
exaly  

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

New England Journal of Medicine, 2015
Torben Plesner, Jacob P Laubach, Hareth Nahi   +2 more
exaly  

Daratumumab in multiple myeloma

Cancer, 2019
Ajay K Nooka, Jonathan L Kaufman, Craig C Hofmeister   +2 more
exaly  

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019
Jakub Krejcik, Yann Abraham, Hugo Ceulemans   +2 more
exaly